Publication: 2887

Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)
      QxMD      Google Scholar   
Citation:
Blood Adv vol 3 (11) 1714-1721
Year:
2019
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
Yes
Biospecimen:
No
SDC:
Yes
Book Volume:
8
Parents:
2990  
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
Novartis, BMS, Bayer  
Grants:
U10CA180821, U10CA180882, U10CA180833, U10CA180836, U10CA180850, U10CA180867  
Corr. Author:
 
Authors:
                 
Networks:
CA043, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-OH007   
Study
Alliance-A151614
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-10201, CALGB-10503, CALGB-10603, CALGB-10801, CALGB-11001
Phases:
N/A, 2, 3
Keywords:
20, 25, Clinical Trials and Observations